Joseph Kennedy To Lead US Delegation To Good Friday Agreement Anniversary
President Joe Biden has announced the designation of a Presidential Delegation that will attend the 25th Anniversary of the Belfast/Good Friday Agreement in Belfast, Northern Ireland.
The delegation will participate in the Agreement Twenty-Five conference hosted by Queen’s University Belfast to mark the signing of the agreement and attend the Anniversary Dinner at Hillsborough Castle.
Joseph Kennedy III, Special Envoy to Northern Ireland for Economic Affairs, will lead the delegation.
Jane Hartley, U.S. Ambassador to the U.K. and Northern Ireland; Claire D. Cronin, U.S. Ambassador to Ireland; Dr. Amanda Sloat, Special Assistant to the President and Senior Director for Europe, National Security Council; and Paul Narain, Consul General in Belfast, are the othjer members of the delgation.
The Belfast Agreement, also known as the Good Friday Agreement, brought an end to 30 years of conflict in Northern Ireland between its Protestant majority and large Catholic minority.
The deal, signed on 1998 April 10 between parties on all sides of the religious and political divide in Belfast, paved the way for power-sharing in Northern Ireland.
The historic deal is being commemorated in a series of events in April. President Joe Biden last week visited Northern Ireland to mark the anniversary.
Viavi Solutions Stock Slips 8% After Revenue Outlook Lowered
Shares of Viavi Solutions Inc. (VIAV) are slipping over 8% on Monday morning after the company lowered its revenue outlook for the third quarter.
VIAV is currently trading at $9.35, down $0.89 or 8.69%, on the Nasdaq. The stock opened its trading at $9.37 after closing Friday’s trading at $10.24. The stock has traded between $8.90 and $16.00 in the past 52-week period.
For the third quarter, preliminary revenue is expected to be between $246 million and $248 million, as compared to prior guidance of $256 million to $276 million.
Analysts polled by Thomson Reuters currently estimate revenues of $269.48 million.
According to the company, the outlook was lowered due to weakness in its NSE segment that experienced higher than expected pullback in demand for Lab products.
“The pullback in R&D spend at network equipment manufacturers (NEMs) and semiconductor companies was much higher than anticipated leading to revenue and non-GAAP operating margin coming in below the lower end of our guidance” said Oleg Khaykin, VIAVI’s President and Chief Executive Officer. “The spending conservatism and rapid slowdown that we saw in the Service Provider and Data Center spend at the end of fiscal first quarter is now percolating down to the system and component suppliers.”
Roblox Falls 11% On March Performance
Roblox Corp. (RBLX) shares are sliding more than 11 percent on Monday morning trade after the company reported around two percent reduction in average booking per daily active users, between $3.73 and $3.85. The company said foreign currency fluctuations weighed on the March performance and the change in year-over-year March 2023 average bookings per daily active user would have been down 1 percent.
Currently, shares are at $40.42, down 11.55 percent from the previous close of $45.70 on a volume of 9,196,599.
Moderna Stock Slips 7%
Shares of Moderna, Inc. (MRNA) are slipping over 7% on Monday morning. Previous day, Moderna and Merck & Co. Inc. announced that a cancer vaccine developed by them showed promising results in a key study, reducing the risk of recurrence or death by 44%.
MRNA is currently trading at $145.57, down $11.53 or 7.34%, on the Nasdaq. The stock opened its trading $159.95 after closing Friday’s trading at $157.10. The stock has traded between $115.03 and $217.25 in the past 52-week period.
mRNA-4157 (V940) in combination with Keytruda reduced the risk of recurrence or death by 44% compared to Keytruda alone in stage III/IV melanoma patients with high risk of recurrence following complete resection.
“Today’s results provide further encouragement for the potential of mRNA as an individualized neoantigen therapy to positively impact patients with high-risk resected melanoma,” said Dr. Kyle Holen, M.D. Moderna’s Senior Vice President and Head of Development, Therapeutics and Oncology. “The profound observed reduction in the risk of recurrence-free survival suggests this combination may be a novel means of potentially extending the lives of patients with high-risk melanoma. We look forward to starting the Phase 3 melanoma trial soon and expanding testing to lung cancer and beyond.”
Presto Automation Stock Surges 155%
Shares of Presto Automation Inc. (PRST) are gaining over 155% on Monday morning.
PRST is currently trading at $3.5875, up $2.1875 or 156.2500%, on the Nasdaq, on a volume of 40 million shares, above average volume of 72 thousand. The stock opened its trading at $2.2800 after closing Friday’s trading at $1.4000. The stock has traded between $1.2300 and $10.7000 in the past 52-week period.
Presto Automation operates as a labor automation technology provider in the hospitality industry. The company develops the Presto Smart Dining system (Presto Touch) that offers operations efficiency, guest self-service, and marketing benefits for casual dining operators.
Viavi Solutions Q3 Preliminary Revenue Lower Than Estimates; Stock Down In Pre-Market
Viavi Solutions Inc. (VIAVI), a maker of testing and monitoring equipment, on Monday announced preliminary revenue for the third-quarter, which has missed its previous guidance as well as analysts’ estimates.
Following this news, VIAVI is trading down by 2.15 percent at $10.02 per share in pre-market on the Nasdaq.
For the third-quarter, the company expects preliminary revenue to be in the range of $246 million – $248 million. Earlier, the company had projected revenue of $256 million – $276 million.
Six analysts, on an average, polled by Thomson Reuters expect VIAVI to record revenue of $269.48 million. Analysts’ estimates typically exclude special items.
A decline in preliminary revenue was attributed mainly to a weakness in the company’s NSE segment that experienced higher than expected pullback in demand for Lab products.
Oleg Khaykin, VIAVI’s CEO, said: “…The pullback in R&D spend at network equipment manufacturers (NEMs) and semiconductor companies was much higher than anticipated leading to revenue and non-GAAP operating margin coming in below the lower end of our guidance.”